Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

21 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Sabril Articles

Catalyst Pharma shares fall after mid-stage cocaine addiction trial delayed

27 September 2012

Lundbeck gains US approval for Sabril

24 August 2009

Denmark's Lundbeck to buy Ovation for $900M

16 February 2009

Ovation's Sabril recommended for epilepsy

19 January 2009

Anti-addiction drug may treat obesity

1 September 2008

FDA earmarks Sabril for fast-track review

4 February 2008

Japanese study group urges Zolinza appro

7 May 2007

Ovation gains two CNS drugs from Aventis

19 April 2004

Higher-Priced Drugs Set To Expand Epilepsy Market

12 February 1996

USA Lags Foreign Approvals, PhRMA Demonstrates

16 October 1995

Communication Gap In Epilepsy Management In UK?

8 May 1995

....And Marion Merrell Dow Updates On R&D Efforts

10 April 1995

Hoechst Offers $7 Billion For Marion Merrell Dow

6 March 1995

Vigabatrin NDA Filed In The USA

18 July 1994

LAMICTAL APPROVED FOR PEDIATRIC USE

23 May 1994

SANDOZ AND MMD IN COPROMOTION

28 February 1994

THE DAWN OF A NEW ERA FOR EPILEPSY

27 September 1993

NEW HOPES FOR EPILEPSY TREATMENT

12 July 1993

1991 A "SUPERB" YEAR FOR MARION MERRELL DOW

13 April 1992

Showing 1-19 of 19 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Elan makes "transformational" acquisitions and a divestment
  • Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
  • SciClone gains China rights to Zensun's Neucardin
  • Bristol-Myers' data on Yervoy and nivolumab causes a stir
  • HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
  • Elan makes "transformational" acquisitions and a divestment
  • Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
  • SciClone gains China rights to Zensun's Neucardin
  • Bristol-Myers' data on Yervoy and nivolumab causes a stir
  • HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS